Physician profile
Gary Gray
NPI 1922273796
$7,165.20
in general payments reported to CMS, 2019-2025
34 companies · $1,393 in 2025
The $1,393 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,185 · 2020: $1,037 · 2021: $751 · 2022: $651 · 2023: $935 · 2024: $1,213 · 2025: $1,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,541.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,069.60 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $854.49 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $719.68 | 2019-2022 | |
| Novo Nordisk INC | $668.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $548.83 | 2021-2025 | |
| Amarin Pharma, INC. | $424.02 | 2019-2021 | |
| Lilly USA, LLC | $328.64 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Sumitomo Pharma America, INC. | $307.77 | 2023-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $289.41 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $242.37 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $209.53 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $209.50 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $163.19 | 2023-2025 | |
| Astellas Pharma US INC | $133.33 | 2020-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.23 | 2019-2024 | Jardiance, Ofev |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $95.81 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $93.21 | 2019-2025 | Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $91.82 | 2019-2024 | Trintellix |
| Dexcom, INC. | $70.17 | 2024-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $68.28 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $65.57 | 2024 | Voquezna |
| Eisai INC. | $48.12 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $47.87 | 2019-2025 | Zoryve |
| Esperion Therapeutics, INC. | $44.19 | 2021-2025 | Nexletol |
| Xeris Pharmaceuticals, INC. | $39.74 | 2024 | Keveyis |
| Abbott Laboratories | $37.10 | 2021-2022 | |
| Shield Therapeutics INC | $33.74 | 2023-2024 | Accrufer |
| Edwards Lifesciences Corporation | $22.96 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Horizon Therapeutics Plc | $21.29 | 2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $20.64 | 2021 | |
| Antares Pharma, INC. | $19.80 | 2024 | Xyosted |
| Almatica Pharma LLC | $18.78 | 2024 | Loreev Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.29 | 2025 | Caplyta |
| Mannkind Corporation | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.